SCHEMBL4839658

SCHEMBL4839658

COc1cc2c(cc1OC)C(CCN1CCC(C(=O)N3CCCCC3)(c3ccccc3)CC1)N(C(=O)C1CCCCCC1)CC2

nearest known ligand 0.63

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MTNR1B P49286 14/20 0.63
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP2C19 P33261 1/20 0.45
RECQL P46063 1/20 0.45
MTNR1A P48039 1/20 0.42
GRIN2C Q14957 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839308 0.96 MTNR1B (0.62) MTNR1BNPSR1HSD17B10ALDH1A1CYP1A2
SCHEMBL4838275 0.88 NPSR1 (0.53) MTNR1BNPSR1ALDH1A1CYP1A2CYP3A4
SCHEMBL4833277 0.80 MTNR1B (0.61) MTNR1BALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL4839169 0.80 NPSR1 (0.54) MTNR1BNPSR1ALDH1A1
SCHEMBL4841461 0.79 MTNR1B (0.60) MTNR1BALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL4833547 0.79 NPSR1 (0.52) MTNR1BNPSR1ALDH1A1
SCHEMBL4839235 0.79 MTNR1B (0.55) MTNR1BALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL4838911 0.79 KCNA3 (0.52) MTNR1BNPSR1ALDH1A1
SCHEMBL4839831 0.78 KCNA3 (0.53) NPSR1ALDH1A1
SCHEMBL4838194 0.76 MTNR1B (0.53) MTNR1BALDH1A1CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP claimed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 MTNR1B 621/4885NPSR1 167/4885HSD17B10 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.